Jun 09, 2021 / 07:50PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Great. Good afternoon, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs. And today, we're very pleased to be hosting Royalty Pharma at our virtual conference.
Joining us from the company today, we have Terry Coyne, the company's CFO; and Marshall Urist, who is Co-Head of Research and Investments. Thank you both so much for taking time out of your day to join us today.
I'm going to turn it over to Terry for some opening remarks, and then we'll launch into some Q&A.
Terrance Coyne - Royalty Pharma Plc - Executive VP & CFO
Great. Thanks, Terence, and thanks to Goldman Sachs for hosting us today.
Before I get started, I'd like to remind everyone that the information discussed today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our 10-K on file with the SEC for a description of these risks.
So Royalty
Royalty Pharma Plc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers